Communiqués Agilent Technologies, Inc.

Actions

A

US00846U1016

Equipement et technologie médicale avancés

Temps réel estimé Cboe BZX 19:36:36 23/09/2026			Varia. 5j.	Varia. 1 janv.
164,48 ^USD	-1,66%		+7,20%	+21,08%

13:05	Transcript : Agilent Technologies, Inc. Presents at U.S. All Stars Conference, Sep-23-2026 09:00 AM
21/09	Agilent Technologies, Inc. : Goldman Sachs reste à l'achat	ZM

Communiqués

21/09	Agilent Launches TapeStationDx Systems for Clinical NGS Sample Quality Control	BU
16/09	CORRECTING and REPLACING Agilent Announces Cash Dividend of 25.5 Cents per Share	BU
10/09	Agilent to Participate in J.P. Morgan U.S. All Stars Conference	BU
08/09	Agilent Announces Retirement of Board Chair Koh Boon Hwee, Appointment of Glenn Boehnlein to Board of Directors	BU
04/09	Agilent Expands Digital Pathology Offering with U.S. Launch of the Agilent S540MD Slide Scanner System	BU
01/09	Agilent Introduces the Cary 635 FTIR Spectrometer	BU
26/08	Agilent Technologies : Q3'26 Results Presentation	PU
26/08	Agilent: Fiscal Q3 Earnings Snapshot	AQ
26/08	Agilent Reports Third-Quarter Fiscal Year 2026 Financial Results	BU
29/07	Agilent Research Catalyst Award Presented to Eastern Institute of Technology, Ningbo	BU
28/07	Agilent to Announce Third-Quarter Fiscal Year 2026 Financial Results on Aug. 26	BU
23/07	Agilent Receives EU Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma	BU
14/07	Agilent Receives FDA Approval for PD-L1 IHC 28-8 pharmDx in Esophageal Squamous Cell Carcinoma (ESCC), Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinoma	BU
08/07	Agilent Expands Altura Portfolio with Inert Size Exclusion and PLRP-S Columns for Biotherapeutic Analysis	BU
01/07	Agilent Launches AI-Driven Analysis Module for Agilent xCELLigence RTCA eSight	BU
25/06	Agilent Completes Acquisition of Biocare Medical	BU
03/06	Agilent, OpenAI, BCG Collaborate to Accelerate Customer-Focused, AI-Driven Scientific Innovation	BU
02/06	Agilent Receives FDA Approval for Expanded Use of PD-L1 IHC 22C3 pharmDx on Dako Omnis in Esophageal Squamous Cell Carcinoma, Triple-Negative Breast Cancer, Cervical Cancer, and Gastric or Gastroesophageal Junction Adenocarcinoma	BU
01/06	Agilent Technologies : and Sound Analytics Collaborate to Advance LC/MS Workflows for Drug Metabolism Research	PU
29/05	Agilent Technologies : Showcases Integrated Mass Spectrometry and Chromatography Solutions at ASMS 2026	PU
28/05	Agilent Introduces OpenLab Sync to Support Guided, Digital Execution in the Laboratory	BU
27/05	Agilent: Fiscal Q2 Earnings Snapshot	AQ
27/05	Agilent Reports Second-Quarter Fiscal Year 2026 Financial Results	BU
26/05	Agilent Launches Multi-Attribute Method (MAM) Solution for BioPharma Quality Control	BU
26/05	Agilent Launches New GC Systems with GC Assist to Improve Laboratory Efficiency and Data Quality	BU